EK -Local recommendations (Gastro-intestinal)
Use documents past their review date with caution
Chronic bowel disorders
| Recommendation | Approval date | Review date |
| St Marks formula electrolyte solution (updated) | February 2018 | February 2022 |
| PR2019-07 EKPG Recommendation Probiotics for adults with lactose intolerance IBS and IBD | April 2019 | April 2022 |
| Kent and Medway INFLAMMATORY BOWEL DISEASE (IBD) (ADULTS) HIGH-COST DRUG (HCD) PATHWAY | December 2023 | December 2025 |
| SERMOG-01: Dual biological therapy for inflammatory bowel disease (IBD) in adults | December 2024 | December 2026 |
| PR 2024-10 Dose escalation of subcutaneous infliximab for inflammatory bowel disease (IBD) | June 2024 | June 2026 |
Constipation
| Recommendation | Approval date | Review date |
| Naloxegol -EKPG Recommendation | Oct 2015 | April 2021 |
| Lubiprostone Prescribing Guidelines - EKPG | Sept 2014 | April 2021 |
| Place of Linaclotide in NICE IBS pathway | October 2020 | October 2021 |
| 020.20 PR 2019-16 Linaclotide for irritable bowl syndrome with constipation (IBS-C) in adults | July 2019 | July 2020 |
Diarrhoea
| Recommendation | Approval date | Review date |
| EKPG Recommendation - Diarrhoea Assessment and Management in Adults | April 2016 | April 2019 |
Disorders of gastric acid and ulceration
| Recommendation | Approval date | Review date |
| Hypomagnesaemia in Adults – Primary Care Guide | August 2023 | August 2025 |
| Omeprazole Oral suspension for Paediatrics in Primary Care Position Statement | December 2023 | December 2025 |
| Proton Pump Inhibitor (PPI) Oral suspension for Adults Primary Care Position Statement | December 2023 | December 2025 |
GI Smooth Muscle Spasm
| Recommendation | Approval date | Review date |
| Gastro-intestinal (GI) Anti-spasmodics – Dicycloverine and Propantheline prescribing not supported | October 2023 | October 2025 |
Liver disorders and related conditions
| Recommendation | Approval date | Review date |
| Rifaximin GP summary, EKPG recommendation | January 2016 | April 2021 |
| Rifixamin pathway v1.3 EKPG recommendation | April 2019 | April 2022 |
Rectal and anal disorders
| Recommendation | Approval date | Review date |
| EKPG Pathway for the management of Anal Fissures in primary care | June 2017 | June 2020 |
| EKPG Recommendation, Botulinum Toxin for chronic anal fissures | May 2016 | April 2021 |
Ventral hernias
| Recommendation | Approval date | Review date |
| PRGC PR 2022-15 BTX for ventral hernia | June 2022 | June 2024 |
- On Formulary Preferred
- On Formulary Second Line
- On Formulary Third Line
- Specialist Initiation
- Secondary Care Only
- Not Approved for Formulary